← Back to screener

Xeris Biopharma Holdings, Inc. XERS

Rank #2489 · Nasdaq · $1.8B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
13.7
P/E
-29.7
P/B
40.92
ROE
-137.8%
Op. Margin
-26.8%
Debt Ratio
780%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -29.7x, P/B 40.92x. Ranks in the top 84% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -137.8%. Ranks in the top 90% of the universe.

Safety ★☆☆☆☆
Poor

Debt ratio 780%. Ranks in the top 86% of the universe. Above 200% signals meaningful leverage risk.

Growth ★★★★★
Excellent

Revenue growth of 48.7% year over year. Ranks in the top 8% of the universe.

Growth is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2021$0.0B$-0.1B$-0.1B$0.0B-408.8869
2022$0.0B$-0.1B$-0.1B$0.0B-232.2619
2023$0.0B$-0.1B$-0.1B$0.0B-232.2887
2024$0.1B$-0.1B$-0.1B$0.1B-74.3346
2025$0.2B$-0.0B$-0.1B$0.0B-26.8780

← See the full screener